?? ?Levocetirizine Dihydrochloride (CAS 130018-87-0) - Product Overview?
Levocetirizine Dihydrochloride is a ?third-generation H1-receptor antagonist? (molecular formula: ?C??H??ClN?O?·2HCl?, MW: 461.81) designed to treat ?allergic conditions? such as allergic rhinitis and chronic idiopathic urticaria. As the ?R-enantiomer of cetirizine?, it demonstrates enhanced efficacy and safety with rapid onset (1-3 hours) and 24-hour duration of action. This white to off-white crystalline powder (HPLC purity ≥99%) is stable under ?2-8°C storage?, making it ideal for pharmaceutical formulations.

?? ?Key Advantages?
?? ?High Potency?: Targets H1-receptors with ?>2x higher affinity? than (S)-cetirizine, reducing histamine-driven symptoms effectively.
?? ?Rapid Relief?: Achieves peak plasma concentration within ?1-3 hours?, offering fast symptom control.
?? ?Safety Profile?: Minimal sedation risk compared to first-generation antihistamines.
?? ?Solubility?: Water solubility ≥23 mg/mL for easy formulation.

?? ?Applications?

1. ?Allergy Management?: First-line therapy for ?allergic rhinitis? and ?chronic urticaria?.

2. ?Research?: Tool for studying histamine receptor mechanisms and enantiomer-specific drug effects.

3. ?Drug Development?: Used in oral tablets, syrups, and pediatric formulations.

?? ?Quality Certifications?

• Complies with ?USP/EP? pharmacopeial standards.

• Rigorously tested via ?HPLC (≥99%)?, ?GC?, and ?NMR? for batch consistency.

• Produced in ?GMP?-certified facilities with ISO 9001 compliance.

?? ?Market Insights?
The global antihistamine market is projected to grow at ?6.2% CAGR through 2030?, driven by rising allergy prevalence. Levocetirizine holds ?>25% market share? in prescription H1 antagonists, favored for its enantiomeric purity and safety.